MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Abeona Therapeutics Inc

Open

4.87 3.62

Overview

Share price change

24h

Current

Min

4.51

Max

4.9

Key metrics

By Trading Economics

Employees

136

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+298.93% upside

Market Stats

By TradingEconomics

Market Cap

4.4M

218M

Previous open

1.25

Previous close

4.87

Abeona Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

22 Apr 2024, 23:00 UTC

Major Market Movers

Abeona Therapeutics Shares Down 53% After FDA Complete Response Letter

Peer Comparison

Price change

Abeona Therapeutics Inc Forecast

Price Target

By TipRanks

298.93% upside

12 Months Forecast

Average 18.67 USD  298.93%

High 25 USD

Low 15 USD

Based on 3 Wall Street analysts offering 12 month price targets forAbeona Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Financials

$

About Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.